Tvaster Genkalp: Early Cancer Detection with Liquid Biopsy
Cancer diagnosis has traditionally relied on invasive procedures such as biopsies, which not only cause discomfort to patients but also delay the detection of cancerous cells. However, a Chennai-based startup, Tvaster Genkalp, is revolutionizing cancer care with its non-invasive liquid biopsy test, Episcreen Liver, for early detection of hepatocellular carcinoma (HCC). Founded in 2021 by Srikar Raman and K Sreedurgalakshmi, the company has tested over 1,400 patients, raised $1.25 million in funding, and is driven by a mission to make advanced cancer diagnostics accessible.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, affecting millions of people worldwide. Early detection is crucial in treating HCC, as it is more likely to be curable in its early stages. However, traditional diagnostic methods, such as imaging techniques like CT and MRI scans, are often inaccurate and may require multiple procedures to confirm the diagnosis.
Tvaster Genkalp’s Episcreen Liver liquid biopsy test is a game-changer in the field of cancer detection. This non-invasive test involves analyzing a patient’s blood sample for biomarkers that are present in the blood when cancerous cells are present. The test can detect HCC at an early stage, even before symptoms appear, allowing for timely treatment and improving patient outcomes.
The Episcreen Liver test uses advanced machine learning algorithms and AI-powered analytics to identify specific biomarkers in the blood that are associated with HCC. This eliminates the need for invasive procedures, reducing the risk of complications and improving patient comfort.
The test has been tested on over 1,400 patients to date, with results showing a high accuracy rate in detecting HCC. The company has also partnered with several leading hospitals and research institutions in India to further validate the test’s efficacy.
The development of Episcreen Liver is a significant achievement for Tvaster Genkalp, considering the challenges faced in the development of liquid biopsy tests. The company’s founders, Srikar Raman and K Sreedurgalakshmi, have extensive experience in the biotech industry and have worked tirelessly to develop the test.
“We are thrilled to have developed a non-invasive liquid biopsy test that can detect HCC at an early stage,” said Srikar Raman, Co-Founder of Tvaster Genkalp. “Our goal is to make advanced cancer diagnostics accessible to patients worldwide, and we believe that Episcreen Liver is a crucial step towards achieving that goal.”
The funding received by Tvaster Genkalp will be used to further validate the test’s efficacy, expand its reach to more patients, and explore opportunities for collaborations with other biotech companies and research institutions.
The development of Episcreen Liver has significant implications for the field of cancer care. Early detection of HCC can improve patient outcomes, reduce healthcare costs, and enhance quality of life for patients. The test also has the potential to revolutionize the way cancer is diagnosed, making it more accessible and non-invasive.
In conclusion, Tvaster Genkalp’s Episcreen Liver liquid biopsy test is a significant breakthrough in the field of cancer detection. The test’s ability to detect HCC at an early stage, non-invasively, has the potential to improve patient outcomes and reduce healthcare costs. With its high accuracy rate and potential for widespread adoption, Episcreen Liver is poised to revolutionize the way we diagnose and treat HCC.
Source:
https://ascendants.in/the-ascendants/tvaster-genkalp-liver-cancer-detection/
